Car­lyle finds its first big biotech bet af­ter team­ing with Abing­worth

Car­lyle Group and Abing­worth are putting their com­bined pow­ers to use, ex­tend­ing a cus­tom fi­nanc­ing deal to an Aus­tralian pub­lic com­pa­ny that’s in the mid­dle of Phase III stud­ies in wet age-re­lat­ed mac­u­lar de­gen­er­a­tion.

Mon­ey — $170 mil­lion of it in to­tal — is just the first part. Through their new de­vel­op­ment crew at Launch Ther­a­peu­tics, the in­vestors are al­so to lend clin­i­cal, reg­u­la­to­ry and com­mer­cial ex­per­tise to Opthea as it tries to ush­er its OPT-302 to the mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER